As per enclosed letter.

Exceptional itemEBITDA margin compressionResults View source PDF Explain this filing

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.6%Reaction day

₹6900.00

prior close

₹6750.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+1.3%-2.9% vs market

Pharmaceuticals peers, median of 166sector+0.8%-2.4% vs sector

On the reaction day the stock moved 2.9 pts less than Nifty 100 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.1

10m

+1.4

15m

+1.1

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.6+1.3-2.9+0.8-2.4

Next day

-2.3+1.0-3.3+1.5-3.7

-1.6+1.2-2.8+1.5-3.1

-3.2-0.2-2.9+0.9-4.0

-5.0-1.1-3.9+0.5-5.5

-5.7-0.7-5.0+0.9-6.6

-4.6-1.0-3.6+0.5-5.1

15d

-2.5+1.5-3.9+1.6-4.1

-2.9+1.8-4.7+3.6-6.5

+7.8+1.7+6.1+5.5+2.3

+25.7+3.4+22.4+8.2+17.5

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Divis Laboratories reported strong full-year results with standalone PAT growing 18% to ₹2,607 crore from ₹2,209 crore. Consolidated PAT rose 17.2% to ₹2,568 crore from ₹2,191 crore. Revenue from operations grew 13% standalone (₹10,388 crore) and 12.8% consolidated (₹10,560 crore). The company recorded ₹74 crore as an exceptional item due to the impact of new Labour Codes. Foreign exchange gains boosted Other Income significantly to ₹506 crore standalone vs ₹352 crore in FY2024-25. The Board recommended a dividend of ₹30 per share (1500%) consistent with the prior year. Capital work-in-progress more than doubled to ₹2,113 crore indicating major expansion underway. Statutory auditors issued unmodified opinions on both standalone and consolidated results.

Likely market impact

The 17-18% PAT growth demonstrates solid operational performance, though below 20% threshold. The ₹74 crore exceptional charge and higher depreciation from expansion may pressure near-term margins. Strong forex gains boosted bottom-line but are volatile. Ongoing capacity expansion signals confidence in future demand.